Investor Insights

This summary was created by AI, based on 12 opinions in the last 12 months.

Vertex Pharmaceuticals Inc. is receiving positive reviews from experts regarding its cystic fibrosis franchise and its potential for growth in other therapeutic areas. The stock has shown impressive gains and is considered to be a high-quality biopharma company with strong potential for long-term success. However, there are concerns about the stock being overvalued and recommendations to take profits. Overall, Vertex Pharmaceuticals Inc. is seen as a well-performing company with good momentum and a diverse product portfolio.

Consensus
Positive
Valuation
Overvalued
BUY

Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.

Pharma & Healthcare
HOLD

Even at this all time high don't sell. They're working on non-addictive painkillers

Pharma & Healthcare
HOLD

It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.

Pharma & Healthcare
BUY

This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.

Pharma & Healthcare
BUY

Likes it for its CF franchise.

Pharma & Healthcare
PARTIAL SELL

Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.

Pharma & Healthcare
BUY

PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 57.9%)Stochchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX has triggered its stop at $350.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment gain of 44%, when combined with our previous recommendations.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 88.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $330) to $350 at this time.  

Pharma & Healthcare
BUY

They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.

Pharma & Healthcare
PARTIAL SELL

A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 72.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To be disciplined, we recommend trailing up the stop (from $320) to $330 at this time.  

Pharma & Healthcare
BUY

Not too expensive. They report next week. They have good momentum and products.

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 71.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  We now recommend to trail up the stop (from $300) to $320.  

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 03/23, Up 57.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  We recommend trailing up the stop to $300 at this time.  

Pharma & Healthcare
Showing 1 to 15 of 31 entries

Vertex Pharmaceuticals Inc.(VRTX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 10

Stockchase rating for Vertex Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Vertex Pharmaceuticals Inc.(VRTX-Q) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q

Is Vertex Pharmaceuticals Inc. a buy or a sell?

In the last year, 10 stock analysts published opinions about VRTX-Q. 7 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..

Why is Vertex Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Vertex Pharmaceuticals Inc. worth watching?

10 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Vertex Pharmaceuticals Inc. stock price?

On 2024-10-07, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $448.6.